Recent Articles from GlobeNewswire

AI- enhanced solution makes validated measurement faster to run, easier to repeat, and simpler to act on

Hod Hasharon, Israel, March 04, 2026 (GLOBE NEWSWIRE) -- Allot Ltd. (NASDAQ: ALLT, TASE: ALLT), a leading global provider of innovative Security-as-a-Service (SECaaS) and network intelligence solutions for communications service providers and enterprises, today announced that management will be meeting with investors at the Cantor Fitzgerald Global Technology Conference in New York City on March 11, 2026.

With Harmony, Base44 and an ambitious roadmap ahead, Wix is reshaping how people create in the AI era and expanding the world of what’s possible online

Leading Mexican operator leverages provider’s content ecosystem to diversify casino offering

SYDNEY, March 04, 2026 (GLOBE NEWSWIRE) -- Axi, a trusted global online trading broker, is proud to announce the launch of its Buy Crypto services, an intuitive and straightforward platform designed to eliminate the complexities of cryptocurrency trading.

March 4, 2026

HO CHI MINH CITY, Vietnam, March 04, 2026 (GLOBE NEWSWIRE) -- On-chain perpetual trading is expanding rapidly, recently hitting $1.4 trillion in monthly volume. Yet, traders still face a strict compromise: the smooth execution of centralized exchanges (CEXs) or the self-custody of decentralized platforms. Antarctic is eliminating that trade-off.

— Second clinical candidate from HUTCHMED’s next-generation ATTC platform —

- Earnings Call Scheduled for 8:00 AM ET on March 24, 2026 -

REYKJAVIK, Iceland, March 04, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it will release its fourth quarter and full year 2025 financial and operating results on Wednesday, March 18, 2026, after the U.S. markets close.

With over 450,000 sqm and 4,000 employees, GXO’s Polish operations are its largest in Central Europe

Availability of a short formof the 2025 Annual Financial Report

Blaze Pizza Introduces the “Sweet Heat” Pizza, Weekly Tuesday Drops and Additional Themed Surprises for Fans

Tokyo, Tashkent and Barcelona , March 4, 2026 – VEON Ltd. (Nasdaq: VEON), a global digital operator, and Rakuten Group, Inc. today announce that Beeline Uzbekistan, VEON’s digital operator in Uzbekistan, and Rakuten Symphony, a subsidiary of Rakuten Group, have signed a Memorandum of Understanding (MoU) to explore strategic collaborations that support the development of Uzbekistan’s fast-growing digital economy, including on Open RAN development, AI-powered network intelligence and next-generation digital platforms.

Milan, Italy – March 04, 2026 – Tensive S.r.l, a clinical-stage advanced biomaterials medical device company developing REGENERA™ bioresorbable scaffolds for breast reconstruction and tissue marking, today announced that independent investigators from the University of Pisa and the AOUP Breast Center (Pisa University Hospital) presented new data at the European Congress of Radiology (ECR 2026) in Vienna, Austria.

DASSAULT AVIATION RESULTSCONSOLIDATED DATA

Barcelona, Dhaka and Islamabad, March 4, 2026: VEON Ltd. (Nasdaq: VEON), a global digital operator (“VEON”), today announces a partnership with the GSMA’s Mobile for Development Foundation (“GSMA Foundation”) to co-fund digital innovation projects in Pakistan and Bangladesh that are supported by the GSMA Innovation Fund.

Press release4 March 2026 - N° 04  

KELLOGG, Idaho and VANCOUVER, British Columbia, March 04, 2026 (GLOBE NEWSWIRE) -- Bunker Hill Mining Corp. (“Bunker Hill” or the “Company”) (TSX-V: BNKR | OTCQB: BHLL), announces further to its news release dated February 9, 2026, the effective date of its one-for-thirty-five reverse stock split (“Reverse Stock Split”) of the Company’s common stock, par value US$0.000001 (“Common Stock”) and preferred stock, par value US$0.000001 (“Preferred Stock”). The Reverse Stock Split will be effective as of March 6, 2026 (the “Consolidation Date”), and the shares of Common Stock (the “Common Shares”) will commence trading, on a consolidated basis, on the TSX Venture Exchange (the “TSXV”) at market opening on the Consolidation Date. Bunker Hill also wishes to announce, further to its news releases dated February 9, 2026 and February 13, 2026, certain amendments to its LIFE offering of up to 159,735,000 units1 (the “LIFE Units”) of the Company (the “LIFE Offering”), inclusive of the Agents’ Option (as defined herein), as further described below.

Global study reveals disconnect between security awareness and technical controls — as AI-powered attacks accelerate and collaboration tools expand the attack surface

Barcelona and Islamabad, 4 March, 2026: Pakistan’s digital payments ecosystem is evolving from innovation to infrastructure, with Prime Minister Shehbaz Sharif’s Cashless Economy Initiative, supported by the State Bank of Pakistan’s enabling policies, driving momentum at national scale.

NEW YORK and NEW ORLEANS, March 03, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Enphase Energy, Inc. (“Enphase” or the “Company”) (NasdaqGM: ENPH) of a class action securities lawsuit.

NEW YORK and NEW ORLEANS, March 03, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until April 13, 2026 to file lead plaintiff applications in a securities class action lawsuit against uniQure N.V. (NasdaqGS: QURE) (“uniQure” or the “Company”), if they purchased or otherwise acquired the Company’s shares between September 24, 2025 and October 31, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.

NEW YORK and NEW ORLEANS, March 03, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Kyndryl Holdings, Inc. (“Kyndryl” or the “Company”) (NYSE: KD) of a class action securities lawsuit.

NEW YORK and NEW ORLEANS, March 03, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NasdaqGS: RARE) of a class action securities lawsuit.

NEW YORK and NEW ORLEANS, March 03, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Navan, Inc. (“Navan” or the “Company”) (NasdaqGS: NAVN) of a class action securities lawsuit.

NEW YORK and NEW ORLEANS, March 03, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in CoreWeave, Inc. (“CoreWeave” or the “Company”) (NasdaqGS: CRWV) of a class action securities lawsuit.

NEW YORK CITY and NEW ORLEANS, March 03, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until April 21, 2026 to file lead plaintiff applications in a securities class action lawsuit against Corcept Therapeutics Incorporated (NasdaqCM: CORT) (“Corcept” or the “Company”), if they purchased or otherwise acquired the Company’s shares between October 31, 2024 and December 30, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.

NEW YORK and NEW ORLEANS, March 03, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until March 9, 2026 to file lead plaintiff applications in a securities class action lawsuit against Ardent Health, Inc. (“Ardent” or the “Company”) (NYSE: ARDT), if they purchased or otherwise acquired the Company’s securities between July 18, 2024 and November 12, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Middle District of Tennessee.

NEW YORK and NEW ORLEANS, March 03, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until March 23, 2026 to file lead plaintiff applications in a securities class action lawsuit against BellRing Brands, Inc. (NYSE: BRBR), if they purchased or otherwise acquired the Company’s securities between November 19, 2024 and August 4, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In CoreWeave (CRWV) To Contact Him Directly To Discuss Their Options

PASCAGOULA, Miss., March 03, 2026 (GLOBE NEWSWIRE) -- HII’s (NYSE: HII) Ingalls Shipbuilding division authenticated the keel today for the future USS Philadelphia (LPD 32), a Flight II San Antonio-class amphibious transport dock ship.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Varonis (VRNS) To Contact Him Directly To Discuss Their Options

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Tennant (TNC) To Contact Him Directly To Discuss Their Options

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Regencell Bioscience Holdings Limited (NASDAQ:RGC) and Camping World Holdings, Inc. (NYSE:CWH). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.

ROAD TOWN, British Virgin Islands, March 03, 2026 (GLOBE NEWSWIRE) --  Aura Minerals Inc. (Nasdaq: AUGO) (B3: AURA33) (“Aura” or the “Company”) announced today that its issuer credit rating was upgraded by S&P Global Ratings from ‘B+’ to ‘BB-’, with stable outlook and, on national scale, S&P upgraded Aura’s Brazilian National Scale rating from ‘brAA’ to ‘brAA+’ and revised the outlook from positive to stable. The rating on the debentures issued by Aura Almas Mineração S.A. (“Aura Almas”) were also raised from ‘brAA’ to ‘brAA+’.

The $750 million investment marks the first major stadium development in Chicago in more than three decades

VeeaVision enables cybersecure Agentic AI to enhance productivity, privacy, safety, and operational resilience across enterprise environments

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Aardvark Therapeutics, Inc. (“Aardvark” or the “Company”) (NASDAQ: AARD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Brookfield Asset Management Ltd. (NYSE: BAM) (TSX: BAM) (“Brookfield”) announced today that it has established a commercial paper program on a private placement basis. Under the program, Brookfield may issue unsecured commercial paper notes (the “notes”) up to a maximum aggregate amount outstanding at any time of $1 billion. The program is expected to further diversify and strengthen Brookfield’s balance sheet by providing another source of short-term capital. The proceeds from the issuance of any notes will be used for general corporate purposes.

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of FS KKR Capital Corp. (“FSK”) (NYSE: FSK).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

CINCINNATI, March 03, 2026 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the “Company”) (NASDAQ: QIPT; TSX: QIPT)‎, a U.S. based home medical equipment provider, focused on end-to-end respiratory care, today announced the voting results from its special meeting of holders (the “Shareholders”) of common shares (the “Shares”) of the Company held on March 3, 2026 (the “Meeting”) in Sarasota, Florida. The Shareholders voted to approve the special resolution (the “Arrangement Resolution”) approving the plan of arrangement under the Business Corporations Act (British Columbia), involving, among other things, the acquisition by affiliates of Kingswood Capital Management, L.P. and Forager Capital Management, LLC of all of the issued and outstanding Shares (the “Arrangement”) for cash consideration of US$3.65 per Share.

PARSIPPANY, N.J. and CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and funds managed by Blackstone Life Sciences (“BXLS”) today announced a $400 million strategic funding agreement spread across four years to support the continued clinical development of duvakitug. Additionally, under the terms of the agreement, BXLS will be eligible for regulatory and commercial milestones as well as royalties on duvakitug worldwide sales.

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Apollo (NYSE: APO) today announced that its 2026 Annual Meeting of Stockholders will be held virtually on June 8, 2026, at 12:00 pm ET. The record date for the meeting is April 17, 2026. Information on the virtual meeting will be included in the 2026 proxy statement.

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Apollo Global Management, Inc. (“Apollo” or the “Company”) (NYSE: APO).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PROCEPT BioRobotics Corporation (“Procept” or the “Company”) (NASDAQ: PRCT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sunrun Inc. (“Sunrun” or the “Company”) (NASDAQ: RUN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Walker & Dunlop, Inc. (“Walker & Dunlop” or the “Company”) (NYSE: WD).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Eos Energy Enterprises, Inc.  (“Eos” or the “Company”) (NASDAQ: EOSE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ambarella, Inc. (“Ambarella” or the “Company”) (NASDAQ: AMBA).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Franklin BSP Realty Trust, Inc. (“Franklin” or the “Company”) (NYSE: FBRT).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Duolingo, Inc. (“Duolingo” or the “Company”) (NASDAQ: DUOL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of KKR & Co. Inc. (“KKR” or the “Company”) (NYSE: KKR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Xponential Fitness, Inc. (“Xpontential” or the “Company”) (NYSE: XPOF).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of February 28, 2026

SAN FRANCISCO, March 03, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to four new employees to purchase an aggregate of 205,000 shares of the Company's common stock, effective as of March 2, 2026. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).

FRIENDSWOOD, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will host a grand opening celebration for its new corporate headquarters on Tuesday, March 24, 2026, at 3:00 p.m. Central time. The event will take place at the Company’s new campus located at 1500 West Parkwood Avenue in Friendswood, Texas, and will bring together employees, community partners and other invited guests to commemorate the completion of the purpose-built facility.

LEIDEN, Netherlands & CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology platform, today announced that company management will present at the Citizens Life Sciences Conference on Wednesday, March 11, 2026 at 3:25pm ET.

DEER PARK, Ill., March 03, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report fourth quarter and full year 2025 financial results on Thursday, March 19, 2026. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT).

EDMONTON, Alberta, March 03, 2026 (GLOBE NEWSWIRE) -- The Board of Directors for Capital Power Corporation (“Capital Power”) (TSX: CPX) declared a dividend of $0.6910 per share on the outstanding common shares for the quarter ending March 31, 2026. The dividend is payable on April 30, 2026 to shareholders of record at the close of business on March 31, 2026.

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of First Solar, Inc. (“First Solar” or the “Company”) (NASDAQ: FSLR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Driven Brands Holdings Inc. (“Driven” or the “Company”) (NASDAQ: DRVN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of C3.ai, Inc. (“C3” or the “Company”) (NYSE: AI).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Camping World Holdings, Inc. (“Camping World” or the “Company”) (NYSE: CWH).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Oddity Tech Ltd. (“Oddity” or the “Company”) (NASDAQ: ODD).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Company plans to enter into capped call transactions and repurchase shares of its common stock to opportunistically create value for shareholders

BASEL, Switzerland and VANCOUVER, British Columbia, March 03, 2026 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio and a subsidiary of Roivant Sciences Ltd. (Nasdaq: ROIV), and Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that they have entered into a $2.25 billion global settlement with Moderna, Inc. to resolve all U.S. and international enforcement actions involving Moderna’s unauthorized use of Genevant’s and Arbutus’ LNP delivery technology in its COVID-19 vaccines, including Spikevax®.